President of Russia
  • Events
  • Structure
  • Videos and Photos
  • Documents
  • Contacts
  • Search
  • Search this website
President of Russia
Mobile version

President's
website
sections

  • Events
  • Structure
  • Videos and Photos
  • Documents
  • Contacts
  • Search
  • Search
  • For the Media
  • Subscribe
  • Directory
  • Version for People with Disabilities
  • YouTube Channel
  • Русский

President's
website
resources

  • President of RussiaCurrent resource
  • The Constitution of Russia
  • State Insignia
  • Send a Letter
  • Vladimir Putin’s Personal Website

Special
animal welfare
projects

  • Amur tiger
  • Beluga whale
  • Polar bear
  • Snow leopard
  • Far Eastern leopard

Legal
and technical
information

  • About website
  • Using website content
  • Personal data of website users
  • Contact website team

All content on this site is licensed under

Creative Commons Attribution 4.0 International

Presidential Executive Office2023
Events

Meeting with Head of the Federal Medical-Biological Agency Veronika Skvortsova

Vladimir Putin had a working meeting with Head of the Federal Medical-Biological Agency (FMBA) Veronika Skvortsova.

March 15, 2022
14:15
The Kremlin, Moscow
Meeting with Head of the Federal Medical-Biological Agency Veronika Skvortsova.
At a meeting with Head of the Federal Medical-Biological Agency Veronika Skvortsova.

The President was updated on the main areas of the Agency’s activities, including continued efforts against the spread of COVID-19, such as the creation of the AmpliTest diagnostic test kit, the Mir-19 antiviral medication and the Convasel vaccine against the coronavirus.

* * *

President of Russia Vladimir Putin: Good afternoon.

Head of the Federal Medical-Biological Agency Veronika Skvortsova Skvortsova Veronika Skvortsova VeronikaHead of the Federal Medical-Biological Agency (FMBA) : Good afternoon, Mr President.

Our task was to create a new antiviral triad: a test system, an antiviral medication and a vaccine against the coronavirus.

Since March 2020, we have created a series of high-precision and high-sensitivity AmpliTest kits. We started by creating test kits for the SARS-Cov-2 virus and then proceeded to create the AmpliTest system to detect, differentiate and identify its new strains. In particular, we created test kits for the Alpha, Beta and Gamma strains in March 2021 and for Delta and Delta Plus in July 2021. In early December, we created an AmpliTest kit, which can be used to detect three variants of the Omicron strain.

This is important because it helps us to evaluate the epidemiological situation, forecast its future course with due regard to the fundamentally different properties of the Omicron and Delta strains, and to make the necessary calculations for our medical organisations.

In December, we registered a medicine, Mir, the world’s first medication based on viral interference. It is a precision gene engineering preparation that switches off one of the sites of the SARS-CoV-2 virus genome, the most conservative one that does not change in all known lines.

Vladimir Putin: Is it for treatment?

Veronika Skvortsova: Yes, for treatment. Actually, it is an antidote, because it can reduce the viral load by 10,000 times and does not affect the human genome in the process. It is a highly secure medication that is not toxic to humans. But at the same time it works after the first inhalation. When inhaled, dendrimeric peptide in the preparation targets the delivery of the active ingredient to the upper and lower respiratory tracts.

The medication was registered in December, in the first instance, for moderately and seriously ill inpatients. Currently, research is being conducted at the outpatient level in order to use the medication whenever a patient tests positive for COVID-19. It is most effective at this stage. Experience shows that three inhalations per day for five days is enough to turn a positive PCR test into a negative one.

The medication was devised by the Institute of Immunology.

Vladimir Putin: In St Petersburg?

Veronika Skvortsova: … In Moscow, but it is produced by the St Petersburg Research Institute of Vaccines and Serums at its facilities.

Yet another medication, Leitragin, which we registered last year, also switches off one of the sites of the SARS-CoV-2 virus genome. But it is a pathogenic rather than an aetiotropic antiviral medication, which makes it possible to fully prevent the development of cytokine storm in moderately ill patients. It is also an inhaled medicine.

We have 35 research centres, all of which are working hard.

This is all we can report for now, but we have a lot of interesting R&D options under way.

Vladimir Putin: I see. And what about this?

Veronika Skvortsova: This is AmpliTest, as I said, a testing of Omicron and it variants. And Delta, separately.

Vladimir Putin: I see.

Veronika Skvortsova: It is produced by the Centre for Strategic Planning, also the FMBA’s research centre.

Vladimir Putin: All right. Thank you very much.

<…>

Topics

  • Healthcare

Persons

  • Skvortsova Veronika

Publication status

Published in sections: News, Transcripts

Publication date: March 15, 2022, 14:15

Direct link: en.kremlin.ru/d/67987

Text version

Text
2
Photo

Share
Direct link
http://en.kremlin.ru/events/president/news/67987
Share
  • VK
  • LiveJournal
  • Send by email
  • Print
Send by email

Official Website of the President of Russia:

Meeting with Head of the Federal Medical-Biological Agency Veronika Skvortsova

http://en.kremlin.ru/events/president/news/67987

Last updated at March 15, 2022, 19:12

Официальные сетевые ресурсы

Президента России

Official Internet Resources

of the President of Russia

Русский Английский
  • For the Media
  • Version for People with Disabilities
  • Telegram channel
  • YouTube Channel
  • State Insignia
  • Send a Letter
  • Vladimir Putin’s Personal Website
  • Putin. 20 years

Presidential Executive Office
2023